Merck KGAA Ramps Up Immuno-Oncology R&D To Close Ground On Rivals
This article was originally published in The Pink Sheet Daily
The German company is looking to strengthen its cancer immunotherapy portfolio by establishing a dedicated research unit and increasing business development in the field.
You may also be interested in...
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
The efficiency program outlined by the German pharma in February will mean elimination of 500 Merck Serono staff in Switzerland, with another 750 employees being redeployed to Germany, China or the U.S.
AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.